Bevacizumab Plus EGFR-TKIs vs EGFR-TKIs Alone for Advanced EGFR-Mutant NSCLC: A Meta-Analysis.
Background: The goal of this comprehensive meta-analysis was to evaluate the efficacy and safety of combining Epidermal Growth Factor Receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with bevacizumab vs EGFR-TKI monotherapy in advanced non–small-cell lung cancer (NSCLC) patients harboring EGFR-sens...
| Publicado en: | Clinical Medicine Insights: Oncology Vol. 20; pp. 1 - 19 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
1/21/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |